# AI for BD&L and External Innovation
Most large pharmaceutical companies derive 40-60% of their revenue from products that originated externally — through in-licensing, acquisitions, or partnerships. Business development and licensing is therefore not a support function; it is a core strategic capability.
AI for Opportunity Scanning
The universe of potential external opportunities is vast: thousands of biotech companies, academic labs, and other pharma companies with assets that might fill a portfolio gap. Traditional BD scanning relies on conference networking, ClinicalTrials.gov searches, and inbound pitch decks.
AI enables systematic scanning:
`
Scan the external innovation landscape for opportunities that
address the following portfolio gap:
Portfolio gap: [describe the therapeutic area, mechanism, indication, or modality gap]
Unlock this lesson
Upgrade to Pro to access the full content
What you'll learn:
- Use AI to scan and evaluate external innovation opportunities (licensing, acquisition, partnerships)
- Apply AI to model deal economics including milestone structures and royalty scenarios
- Build AI-powered due diligence frameworks that synthesize scientific, clinical, and commercial data